NEW YORK (GenomeWeb News) - Oxford Genome Sciences today said it has received an equity placement from three investors, including previous investors South East Growth Fund and Oxford Capital Partners, and first-time investor Catapult Growth Fund.
 
A company spokesperson declined to disclose the amount of the financing.
 
OGeS develops disease-related proteins for use in cancer diagnostics and therapeutics.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Researchers find that historical factors influence which genes are the most highly studied, the Atlantic reports.

The US National Science Foundation's new sexual harassment policy is to go into effect next month, according to Nature News.

Researchers report using genotyping to tie together illegal ivory shipments and trace them back to a handful of cartels, the New York Times reports.

In Nature this week: genomic ancestry analysis of Sardinians, current noncoding mutations in colorectal cancer, and more.